Nicole Concin was appointed Professor (§98) of Gynecology at MedUni Vienna and Head of the Division of General Gynecology and Gynecologic Oncology at the Department of Obstetrics and Gynecology of MedUni Vienna and University Hospital Vienna at the beginning of 2024.
Nicole Concin’s clinical and research focus is on gynecological oncology. Most recently, she worked in this field at several renowned European institutions, such as the Catholic University of Leuven, Belgium, and the Essen Mitte Clinics, Germany, and held a professorship for Experimental Gynecology at the Medical University of Innsbruck.
Nicole Concin is president of the European Society of Gynecological Oncology (ESGO), chair of the Early Drug Development Network of the European Network of Gynecological Oncological Trial Groups (ENGOT), board member of the International Federation of Gynecology and Obstetrics (FIGO) for women’s cancer and the Austrian Gynecological Oncology Association (AGO Austria) and on the training committee for gynecological malignancies of the European Society of Medical Oncology (ESMO). She has led numerous translational and clinical research projects worldwide and has contributed her expertise to over 85 international clinical trials in gynecologic oncology, several times as Global Coordinating Investigator. In recognition of her achievements, she has received numerous grants and awards, including the Univ.-Prof. Prof. DDr. Karl Fellinger Prize from the Austrian Cancer Society.
Focus on patients: optimal care through research and interdisciplinary cooperation
"Patient-oriented medicine with individualized, empathetic care at the cutting edge is important to me. A basic prerequisite for being able to offer high-quality, evidence-based medicine is active research, which is what characterizes university medicine." At the Division of General Gynecology and Gynecologic Oncology of MedUni Vienna/University Hospital Vienna, Concin wants to offer and further develop patient care, research and teaching at the highest international level in terms of quality and innovation and promote international clinical and scientific cooperation.
Concin would like to focus on early clinical trials and precision medicine in gynecological oncology. "In recent years, we have learned a great deal about the decisive influence of tumor biology on the prognosis of oncological patients. In the treatment of patients with gynaecological malignancies, "molecularly-targeted agents" are increasingly being used, which target specific molecular markers that play a pivotal role in tumour growth and progression, thus enabling individualized treatment. Excellent interdisciplinary cooperation is the key to being able to offer our patients optimal treatment."
In the surgical treatment of patients, Concin relies on the correct indication. Some diseases require extensive (radical) surgery, such as surgery for advanced ovarian cancer. In other specific diseases, however, we are learning that less is more. Above all, Concin would like to further expand the minimally invasive method using robotic surgery for patients with endometrial cancer, but also with endometriosis and other gynecological disorders.
Promoting young talent
Concin wants to pay special attention to inspiring and training the next generation of gynecologists. "Young people are our future," emphasizes Concin, "it is our mission and a pleasure to support young, motivated people in their development, to challenge and encourage them. Equal opportunities for all genders is important to me."